International Drug Prices
Americans pay 278% of what residents of 33 other OECD countries pay for the same prescription drugs. For brand-name drugs, the figure is 422%. These are not estimates from advocacy groups. They come from the RAND Corporation's 2024 analysis, the most methodologically rigorous international price comparison available.
The gap is not new. It has been measured, studied, and debated for decades. It persists because the United States is the only OECD country that does not regulate drug prices at the national level.
The Scale of the Gap
RAND's per-unit price analysis found that US drug prices are 5.5 times the OECD average across all drug types. Compared to the rest of the world, the multiple rises to 7.7 times. Small-molecule drugs cost 8.2 times the international average. Biologics cost 4.7 times.
Country-by-country comparisons sharpen the picture. US prices are 229% of Canadian prices. Compared to Turkey, US prices are 1,028% higher. These are not cherry-picked outliers. The gap holds across virtually every bilateral comparison.
Per Capita Spending (2023, PPP-Adjusted)
| Country | Per Capita Drug Spending |
|---|---|
| United States | $1,713 |
| Germany | $1,158 |
| Switzerland | $1,061 |
| OECD Average | $766 |
| Denmark | $404 |
Total US pharmaceutical spending reached $487 billion in 2024 and is projected to hit $530 billion in 2025. No other country comes close in absolute or per capita terms.
Drug-by-Drug Comparisons
Aggregate data describes the system. Individual drugs describe the experience. The price differences patients face are specific and large.
GLP-1 Receptor Agonists
Ozempic and Mounjaro are the two most prescribed GLP-1 drugs for diabetes and weight management. Both are manufactured by companies headquartered in countries with strict price regulation. Both cost a fraction of their US price everywhere else.
| Drug | US Price | Japan | Other Markets |
|---|---|---|---|
| Ozempic (monthly) | $936 | $169 | ~$83 (France, UK, Australia) |
| Mounjaro (monthly) | $1,023 | $319 | $444 (Netherlands) |
An American patient pays 11 times what a French patient pays for the same Ozempic pen. The drug is made by Novo Nordisk, a Danish company. Denmark's per capita drug spending is $404. This is what price regulation looks like from the outside.
Humira
Humira, the world's best-selling drug for two decades, costs 423% more in the US than in the UK and 186% more than in Germany. AbbVie maintained its US pricing power through an extensive patent thicket that delayed biosimilar entry until 2023. In Europe, biosimilar competition arrived years earlier. To understand how manufacturers build and defend these pricing positions, see how drug prices are set.
Insulin
US gross insulin prices are 9.71 times the OECD average. A vial costs $22.68 in the US and $2.20 in the UK. Even after the manufacturer price cuts of 2023, the US-to-OECD ratio remains roughly 10 to 1. The same molecule, same manufacturing process, same therapeutic effect. For the full price history and what the $35 cap did and did not fix, see insulin prices.
Cancer Drugs
Oncology drugs show the gap at its most consequential.
| Country | Median Monthly Cost |
|---|---|
| United States | $11,755 |
| Germany | $8,300 |
| England | $7,355 |
The US figure alone is striking. The trend is worse. After launch, 74% of cancer drugs in the US received above-inflation price increases. In Germany, the number was zero. German law requires that new drugs demonstrate added clinical benefit to justify any price increase. The US has no equivalent requirement.
Why the Gap Exists
Six structural factors explain the difference. They are not mysterious. Every one has been identified in government reports, academic studies, and congressional testimony. None has been fully addressed.
No national price regulation. The US is the only OECD country without a federal mechanism to set or constrain drug prices. Manufacturers set their own prices at launch and raise them at will. Every other developed country intervenes.
Medicare was prohibited from negotiating. From 1965 to 2025, Medicare was barred by law from negotiating drug prices directly with manufacturers. The Inflation Reduction Act of 2022 created a limited negotiation process for a small number of drugs. For 60 years before that, the largest single payer in the US market accepted whatever price manufacturers set. See Medicare drug price negotiation for what changed and what the limits are.
Fragmented negotiating power. Outside Medicare, drug purchasing is split across thousands of private insurers, employers, hospitals, and government programs. No single entity has the market leverage that national health systems in the UK, France, or Germany hold.
Longer effective patent exclusivity. US manufacturers extend monopoly pricing through patent thickets, product hopping, and pay-for-delay agreements. Effective exclusivity periods in the US routinely exceed those in Europe, where supplementary protection certificates cap extensions at 5 years plus a 6-month pediatric bonus.
PBM opacity. Pharmacy benefit managers negotiate rebates on behalf of insurers but retain a portion of the savings. The rebate system incentivizes higher list prices and obscures the actual transaction price. No reference pricing system exists to anchor negotiations to external benchmarks.
Direct-to-consumer advertising. The US and New Zealand are the only two countries that permit DTC pharmaceutical advertising. US pharma companies spend over $8 billion per year on consumer ads, creating demand for branded products that might otherwise face price competition from generics or therapeutic alternatives.
How Other Countries Control Prices
Other OECD countries use three main mechanisms, often in combination.
International Reference Pricing
Most countries set domestic drug prices by referencing what other countries pay. The number of comparator countries ranges from 4 to 24 depending on the system. Switzerland uses a hybrid: two-thirds of the price is based on an international basket of comparator countries, and one-third is based on Swiss therapeutic comparators (drugs treating the same condition).
Reference pricing creates a network effect. When one country negotiates a lower price, every country that references it benefits. This is also why manufacturers resist transparency. Thirty-two of 34 OECD countries include net price confidentiality clauses in their purchasing agreements. The published price is not the real price. But even the published prices are far below US levels.
Health Technology Assessment
France's Haute Autorité de Santé (HAS) rates every new drug on a five-tier clinical value scale called ASMR (Amélioration du Service Médical Rendu), from I (major improvement) to V (no improvement). The rating directly determines the price the manufacturer can charge and whether the drug is reimbursed.
The UK's National Institute for Health and Care Excellence (NICE) uses a cost-per-QALY threshold (quality-adjusted life year). If a drug costs more than a set amount per QALY gained, NICE can reject it for NHS coverage. Manufacturers must then lower their price or lose access to the UK market.
These systems force a question the US does not ask: does this drug deliver enough clinical value to justify its price?
Patent and Exclusivity Limits
European Supplementary Protection Certificates (SPCs) cap patent extensions at 5 years, with a possible 6-month pediatric extension. This is a hard ceiling. In the US, manufacturers combine regulatory exclusivity, patent thickets, and litigation strategies to maintain effective monopolies far longer.
The Generic Paradox
The US is the most expensive country in the world for brand-name drugs and one of the cheapest for generics. Both facts are true at the same time, and the same structural features explain both.
Generic drugs account for 90% of prescriptions filled in the US, compared to 41% in OECD comparator countries. US generic prices run 33% below the international average. In 2023, generics saved the US healthcare system an estimated $445 billion. For more on how this market works, see the generic drug market.
The reason is competition. The FDA's Abbreviated New Drug Application (ANDA) pathway creates a relatively efficient route to market for generic manufacturers. Multiple competitors drive prices down aggressively. In other countries, reference pricing systems that anchor generic prices to a percentage of the brand price can actually create a price floor. French generics, for example, must be priced at least 40% below the brand. In the US, no such floor exists. Competition drives some generics to pennies per pill.
The paradox reveals the core problem. Where competition exists, the US market delivers low prices. Where monopolies exist, the same market delivers the highest prices in the world. The brand-name market is not competitive. It is protected by patents, regulatory exclusivity, and a payment system that does not push back on price.
Policy Developments
IRA Negotiated Prices
The Inflation Reduction Act authorized Medicare to negotiate prices on a limited number of high-spend drugs. The first round of negotiated prices, announced in 2024, reduced costs for Medicare. But the negotiated prices still ranged from 1.6 to 3.9 times international averages. Medicare did not use international benchmarks in its negotiation methodology. It started from the US list price and worked down. Other countries start from a basket of international prices and work from there.
Most Favored Nation Order
In May 2025, an executive order directed Medicare Part B to pay no more than the lowest price among Canada, Germany, and France for physician-administered drugs. The Most Favored Nation (MFN) approach would, if implemented, directly import international reference pricing into the US system. It faces legal challenges from the pharmaceutical industry and an uncertain implementation timeline.
TrumpRx
In February 2026, CMS launched TrumpRx, a direct-to-consumer discount platform offering reduced prices on approximately 40 drugs. The program bypasses traditional pharmacy channels and PBM intermediaries. It is a retail-facing initiative, not a structural reform. It does not change how prices are set for the broader market.
Public Opinion
Americans are not confused about the problem. In polling, 82% say drug costs are unreasonable. Eighty-eight percent support inflation caps on drug price increases. Eighty-five percent support Medicare negotiation. One in three Americans report skipping medications, cutting pills, or delaying refills because of cost. The policy gap is not a gap in public understanding. It is a gap between what voters want and what the system delivers.